NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1
NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1
AI Summary
Bulleted
Text
Key Insights
- The document discusses the evaluation criteria for Bone Marrow Transplant (BMT) in patients with Refractory Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS).
- It presents a patient perspective, highlighting the shared decision-making process with medical teams and the impact of the patient's quality of life on treatment choices.
- The patient, Beatriz, had SJIA, MAS, and underwent a BMT in 2018, achieving remission by 2024 with minimal medication.
- Key factors in the BMT decision included failed other medications, severity of illness, and availability of a good donor match.
- It explores possible treatment options, classical approaches, and current research on treating different clinical situations associated with SJIA, MAS, and other complications.
#stillsdisease
#sjiafoundation
#sjia
#BMT
#curesjia
Diving into the complexities of Refractory Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS), this details evaluation criteria for Bone Marrow Transplant (BMT). Explore a unique patient perspective, offering insights into the decision-making process, treatment journey, and remission following BMT.
#stillsdisease
#sjiafoundation
#sjia
#BMT
#curesjia
NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1
@SJIA_Foundation3 months ago

Refractory SJIA Patient Perspective & MAS BMT evaluation criteria

- â SJIA, MAS (multiple times), LD
- â 2018: Bone Marrow Transplant (BMT)
- â 2024: In remission, no SJIA medications
- · Just Vitamin D and Calcium
- â Shared decision with medical team - Rheumatology & BMT Teams
- â Beatriz was feeling really sick, quality of life was getting worse everyday.
- â ILD + Pulmonary hypertension - bad outcome in a short period of time.
- â No other medications available, steroid dependant.
- â Good match (unrelated donor, 9/10 match).
- â At least 9 BMTs patients that we know from FB had BMT since 2018
- · Different timing for BMT evaluation
- â MAS Episodes (smoldering/full blown)
- â Lung Disease/Persistent Arthritis/Liver reactionsâ¦
- â HLA DRB 1*15 positive
- â Meds availability in different countries
- â Donor availability
Beatriz, 22 yo, Switzerland
Meds used: Steroids, Methotrexate, Actemra, Canakinumab, Anakinra, Cyclosporin, Tacrolimus
Actual treatment: Complete remission

Our Decision for BMT
Note: Beatriz was HLA DRB 1*15 positive, but in 2018, we didn't know this could be related to LD.
Possible Treatment Options

Quartier P. Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches. J Clin Med . 2022;11(5):1357. Published 2022 Mar 1. doi:10.3390/jcm11051357
Evaluation for BMT depending on center & meds
Is it possible to have an algorithm or protocol for BMT evaluation in SJIA & MAS refractory cases?
Thank you!

1/6

2/6

3/6

4/6

5/6

6/6
Related Jaunts

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 5
@SJIA_Foundation
3 months ago •
217 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 4
@SJIA_Foundation
3 months ago •
231 views

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 1
@SJIA_Foundation
3 months ago •
247 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 2
@SJIA_Foundation
3 months ago •
230 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 3
@SJIA_Foundation
3 months ago •
222 views

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2
@SJIA_Foundation
3 months ago •
270 views

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1
@SJIA_Foundation
3 months ago •
260 views

NextGen 2024: Weaning meds when disease is controlled Session Part 2
@SJIA_Foundation
3 months ago •
344 views
More from author

NextGen 2024: Weaning meds when disease is controlled Session Part 2
@SJIA_Foundation
3 months ago •
344 views

NextGen 2024: Weaning meds when disease is controlled Session Part 1
@SJIA_Foundation
3 months ago •
257 views

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2
@SJIA_Foundation
3 months ago •
270 views

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1
@SJIA_Foundation
3 months ago •
260 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 5
@SJIA_Foundation
3 months ago •
217 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 4
@SJIA_Foundation
3 months ago •
231 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 3
@SJIA_Foundation
3 months ago •
222 views

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 2
@SJIA_Foundation
3 months ago •
230 views